FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205257577> ?p ?o ?g. }

• W4205257577 abstract "<p>Haemangioma is a primary tumour of the microvasculature characterised by active angiogenesis and endothelial cell (EC) proliferation followed by slow regression or involution whereby the newly formed blood vessels are gradually replaced by fibrofatty tissue. These developmental changes have been arbitrarily divided into the proliferative, involuting and involuted phases. The cellular and molecular events that initiate and regulate the proliferation and spontaneous involution of haemangioma remain poorly understood. This study examined the expression of a number of genes known to be associated with angiogenesis. These include members of the signal transducers and activators of transcription (STAT) protein family of transcription factors, STAT-3 and STAT-1, and the endothelial receptor tyrosine kinases, VEGFR-1 and VEGFR-2. While STAT-3, STAT-1 and VEGFR-1 expression was detected in all phases of haemangioma, VEGFR-2 expression was found to be abundant only during the proliferative phase and decreased with ongoing involution. In this study the cellular structures that form capillary-like outgrowths in an in vitro haemangioma explant model were characterised as haemangioma-derived mesenchymal stem cells (HaemDMSCs) while the cells obtained directly from dissociated proliferative haemangioma tissue were defined as haemangioma-derived endothelial progenitor cells (HaemDEPCs). This investigation showed that although the vascular endothelial growth factor (VEGF), a key growth factor for ECs, was able to maintain HaemDEPCs morphology and immunophenotype for a limited period, these cells eventually differentiated into HaemDMSCs, which subsequently differentiated into adipocytes. Furthermore, while VEGF induced significant capillary-like sprouting from tissue explants, both capillary-like sprouting and HaemDMSCs proliferation was inhibited by the addition of AG490, a Janus kinase (JAK) inhibitor which has also been shown to inhibit the STAT protein pathway. These findings indicate that the development and differentiation of a progenitor cell and a stem cell population underlies the aethiopathogenesis of haemangioma and that VEGF and STAT signalling is involved in the programmed life-cycle of haemangioma. The in vitro explant model for haemangioma offers an opportunity to study and identify novel treatment options for haemangioma. Interferon-alpha (IFN ) has been used to treat steroid-resistant haemangioma but is associated with serious side-affects. The tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has been shown to specifically induce apoptosis of cancer cells while sparing normal cells. As IFN has previously been shown to sensitise cells to TRAIL-induced apoptosis, this study examined the efficacy of low dose IFN in combination with TRAIL in the in vitro explant model and also in the purified HaemDMSCs. Results showed that combining IFN with TRAIL led to synergistic inhibition of capillary-like outgrowth. These results indicate that IFN in combination with TRAIL serves as a potential treatment option for haemangioma. In contrast, HaemDMSCs were protected from TRAIL-induced killing. These cells were found to express high levels of the decoy receptors, osteoprotegerin (OPG) and decoy receptor 2 (DcR2). Increased OPG expression was also detected in the extracellular matrix and in the conditioned medium of HaemDMSCs. From these findings, we postulate that the increased level of extracellular OPG by HaemDMSCs is a stress response induced by their in vitro expansion and that secreted OPG functions as a protective shield preventing TRAIL action. The empirical and unsatisfactory nature of the current therapies for haemangioma underscores the importance of a scientific approach to this common tumour. A better understanding of the molecular mechanisms that govern haemangioma is of both clinical and biological interest as it may provide vital information with therapeutic potential for haemangioma and also for other angiogenesis-dependent conditions.</p>" @default.
• W4205257577 created "2022-01-25" @default.
• W4205257577 creator A5065762338 @default.
• W4205257577 creator A9999999999 @default.
• W4205257577 date "2021-11-07" @default.
• W4205257577 modified "2023-09-27" @default.
• W4205257577 title "The Molecular Pathogenesis of Haemangioma" @default.
• W4205257577 doi "https://doi.org/10.26686/wgtn.16945627.v1" @default.
• W4205257577 hasPublicationYear "2021" @default.
• W4205257577 type Work @default.
• W4205257577 citedByCount "0" @default.
• W4205257577 crossrefType "dissertation" @default.
• W4205257577 hasAuthorship W4205257577A5065762338 @default.
• W4205257577 hasAuthorship W4205257577A9999999999 @default.
• W4205257577 hasBestOaLocation W42052575771 @default.
• W4205257577 hasConcept C123012128 @default.
• W4205257577 hasConcept C142724271 @default.
• W4205257577 hasConcept C167734588 @default.
• W4205257577 hasConcept C169760540 @default.
• W4205257577 hasConcept C186720457 @default.
• W4205257577 hasConcept C198826908 @default.
• W4205257577 hasConcept C201750760 @default.
• W4205257577 hasConcept C202751555 @default.
• W4205257577 hasConcept C2777025900 @default.
• W4205257577 hasConcept C2778271429 @default.
• W4205257577 hasConcept C2780394083 @default.
• W4205257577 hasConcept C2781409172 @default.
• W4205257577 hasConcept C28328180 @default.
• W4205257577 hasConcept C2910429298 @default.
• W4205257577 hasConcept C502942594 @default.
• W4205257577 hasConcept C54355233 @default.
• W4205257577 hasConcept C71924100 @default.
• W4205257577 hasConcept C86803240 @default.
• W4205257577 hasConcept C95444343 @default.
• W4205257577 hasConceptScore W4205257577C123012128 @default.
• W4205257577 hasConceptScore W4205257577C142724271 @default.
• W4205257577 hasConceptScore W4205257577C167734588 @default.
• W4205257577 hasConceptScore W4205257577C169760540 @default.
• W4205257577 hasConceptScore W4205257577C186720457 @default.
• W4205257577 hasConceptScore W4205257577C198826908 @default.
• W4205257577 hasConceptScore W4205257577C201750760 @default.
• W4205257577 hasConceptScore W4205257577C202751555 @default.
• W4205257577 hasConceptScore W4205257577C2777025900 @default.
• W4205257577 hasConceptScore W4205257577C2778271429 @default.
• W4205257577 hasConceptScore W4205257577C2780394083 @default.
• W4205257577 hasConceptScore W4205257577C2781409172 @default.
• W4205257577 hasConceptScore W4205257577C28328180 @default.
• W4205257577 hasConceptScore W4205257577C2910429298 @default.
• W4205257577 hasConceptScore W4205257577C502942594 @default.
• W4205257577 hasConceptScore W4205257577C54355233 @default.
• W4205257577 hasConceptScore W4205257577C71924100 @default.
• W4205257577 hasConceptScore W4205257577C86803240 @default.
• W4205257577 hasConceptScore W4205257577C95444343 @default.
• W4205257577 hasLocation W42052575771 @default.
• W4205257577 hasLocation W42052575772 @default.
• W4205257577 hasOpenAccess W4205257577 @default.
• W4205257577 hasPrimaryLocation W42052575771 @default.
• W4205257577 hasRelatedWork W1903631329 @default.
• W4205257577 hasRelatedWork W2022962102 @default.
• W4205257577 hasRelatedWork W2030018140 @default.
• W4205257577 hasRelatedWork W2066495913 @default.
• W4205257577 hasRelatedWork W2081680334 @default.
• W4205257577 hasRelatedWork W2106477041 @default.
• W4205257577 hasRelatedWork W2370359383 @default.
• W4205257577 hasRelatedWork W2734395509 @default.
• W4205257577 hasRelatedWork W2993990633 @default.
• W4205257577 hasRelatedWork W4210768853 @default.
• W4205257577 isParatext "false" @default.
• W4205257577 isRetracted "false" @default.
• W4205257577 workType "dissertation" @default.